New Thinking Needed On Reimbursement Of Cell And Gene Therapies
One-off payment deals for expensive cell and gene therapies cannot be the way forward for healthcare systems aiming for the systematic uptake of these products.
One-off payment deals for expensive cell and gene therapies cannot be the way forward for healthcare systems aiming for the systematic uptake of these products.